Tìm theo
LULICONAZOLE
Các tên gọi khác (1) :
  • NND-502
antifungal agents
Thuốc Gốc
Small Molecule
CAS: 187164-19-8
CTHH: C14H9Cl2N3S2
PTK: 354.277
Luliconazole was approved by the FDA (USA) in November 2013 and is marketed under the brand name Luzu. It is a topical antifungal agent that acts by unknown mechanisms but is postulated to involve altering the synthesis of fungi cell membranes. Luliconazole is also approved in Japan.
Nhận Dạng Quốc Tế & Đặc Tính Hóa Học
Công thức hóa học
C14H9Cl2N3S2
Phân tử khối
354.277
Monoisotopic mass
352.961494097
InChI
InChI=1/C14H9Cl2N3S2/c15-9-1-2-10(11(16)5-9)13-7-20-14(21-13)12(6-17)19-4-3-18-8-19/h1-5,8,13H,7H2/b14-12+
InChI Key
InChIKey=YTAOBBFIOAEMLL-WYMLVPIENA-N
IUPAC Name
2-[(2E)-4-(2,4-dichlorophenyl)-1,3-dithiolan-2-ylidene]-2-(1H-imidazol-1-yl)acetonitrile
Traditional IUPAC Name
2-[(2E)-4-(2,4-dichlorophenyl)-1,3-dithiolan-2-ylidene]-2-(imidazol-1-yl)acetonitrile
SMILES
ClC1=CC=C(C2CS\C(S2)=C(\C#N)N2C=CN=C2)C(Cl)=C1
Độ hòa tan
6.59e-02 g/l
logP
4.07
logS
-3.7
pKa (Strongest Basic)
6.34
PSA
41.61 Å2
Refractivity
101 m3·mol-1
Polarizability
34.27 Å3
Rotatable Bond Count
2
H Bond Acceptor Count
2
H Bond Donor Count
0
Physiological Charge
0
Number of Rings
3
Bioavailability
1
Rule of Five
true
Ghose Filter
true
Dược Lực Học : Luliconazole kills the organisms Trichophyton rubrum and Epidermophyton floccosum, most likely by altering their fungal cell membranes.
Cơ Chế Tác Dụng : Luliconazole was approved by the FDA (USA) in November 2013 and is marketed under the brand name Luzu. It is a topical antifungal agent that acts by unknown mechanisms but is postulated to involve altering the synthesis of fungi cell membranes. Luliconazole is also approved in Japan. The exact mechanism of action for luliconazole's anti-fungal activity is still not known, but luliconazole is thought to inhibit the enzyme lanosterol demethylase. Lanosterol demethylase is needed for the synthesis of ergosterol, which is a major component of the fungus cell membranes.
Dược Động Học :
▧ Absorption :
Although luliconazole is administered topically, clinical studies have shown that after the first dose in patients with tina pedis, a maximum plasma concentration of 0.40 ± 0.76 ng/mL (mean ± SD) occurred in 16.9 ± 9.39 hours (mean ± SD).
▧ Volume of Distribution :
The volume of distribution was not quantified.
▧ Protein binding :
Plasma protein binding of luliconazole is >99%.
▧ Metabolism :
The metabolism of luliconazole has yet to be determined.
▧ Route of Elimination :
The route of elimination of luliconazole has yet to be determined.
▧ Half Life :
The half life of luliconazole has yet to be determined.
▧ Clearance :
The clearance of luliconazole has yet to be determined.
Độc Tính : In clinical trials, no serious toxicity was reported, only local irritation (mild contact dermatitis and cellulitis) at the site of application was found.
Chỉ Định : Luliconazole is indicated in adults aged 18 years and older for the topical treatment of fungal infections caused by Trichophyton rubrum and Epidermophyton floccosum, specifically tinea pedis, cruris, and corporis.
Liều Lượng & Cách Dùng : Cream - Topical - 1%
Dữ Kiện Thương Mại
Nhà Sản Xuất
  • Công ty : Pola Pharma
    Sản phẩm biệt dược : Lulicon
  • Công ty : MEDICIS
    Sản phẩm biệt dược : LUZU
Tài Liệu Tham Khảo Thêm
drugbank
http://www.drugbank.ca/drugs/DB08933
KEGG Drug
http://www.genome.jp/dbget-bin/www_bget?drug:D01980
National Drug Code Directory
http://www.hipaaspace.com/Medical_Billing/Coding/National.Drug.Codes/PDF/99207-850-30
RxList
http://www.rxlist.com/luzu-drug.htm
Drugs.com
http://www.drugs.com/ingredient/luliconazole.html
... loading
... loading